ArticleScientific reports2016
Four microRNAs Signature for Survival Prognosis in Colon Cancer using TCGA Data.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- A Highly Sensitive Urinary Exosomal miRNAs Biosensor Applied to Evaluation of Prostate Cancer Progression.Bioengineering (Basel, Switzerland) · 2022Article
- Pseudouridylate Synthase 7 Promotes Cell Proliferation and Invasion in Colon Cancer Through Activating PI3K/AKT/mTOR Signaling Pathway.Digestive diseases and sciences · 2022Article
- A Three-Genes Signature Predicting Colorectal Cancer Relapse Reveals LEMD1 Promoting CRC Cells Migration by RhoA/ROCK1 Signaling Pathway.Frontiers in oncology · 2022Article
- Nanomaterial-Based Fluorescence Resonance Energy Transfer (FRET) and Metal-Enhanced Fluorescence (MEF) to Detect Nucleic Acid in Cancer Diagnosis.Biomedicines · 2021Review
- Construction of five microRNAs prognostic markers and a prognostic model for clear cell renal cell carcinoma.Translational cancer research · 2021Article
- Competing Endogenous RNA in Colorectal Cancer: An Analysis for Colon, Rectum, and Rectosigmoid Junction.Frontiers in oncology · 2021Article
- Identification of an alternative splicing signature as an independent factor in colon cancer.BMC cancer · 2020Article
- Transcription factor expression as a predictor of colon cancer prognosis: a machine learning practice.BMC medical genomics · 2020Article
- A Novel Seventeen-Gene Metabolic Signature for Predicting Prognosis in Colon Cancer.BioMed research international · 2020Article
- MicroRNAs Associated With Colon Cancer: New Potential Prognostic Markers and Targets for Therapy.Frontiers in bioengineering and biotechnology · 2020Article
- A network view of microRNA and gene interactions in different pathological stages of colon cancer.BMC medical genomics · 2019Article
- IL-2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation?Immunity, inflammation and disease · 2019Article
- MicroRNA expression profiling provides novel insights into immune-related pathways involved in gastric cancer.Medical oncology (Northwood, London, England) · 2019Article
- Identification of Differently Expressed Genes Associated With Prognosis and Growth in Colon Adenocarcinoma Based on Integrated Bioinformatics Analysis.Frontiers in genetics · 2019Article
- A Five-microRNA Signature as Prognostic Biomarker in Colorectal Cancer by Bioinformatics Analysis.Frontiers in oncology · 2019Article
- The role of PEG3 in the occurrence and prognosis of colon cancer.OncoTargets and therapy · 2019Article
- Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.Molecular oncology · 2018Article
- Prognostic value of microRNAs in colorectal cancer: a meta-analysis.Cancer management and research · 2018Article
- Four-miRNA signature as a prognostic tool for lung adenocarcinoma.OncoTargets and therapy · 2018Article
- Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to develop microRNA expression signature for colon cancer survival prognosis based on the Cancer Genomic Common database. miRNAs levels between colon cancer and non-cancer tissues were screened by t-test (p < 0.05). Kaplan-Meier survival method was used to discriminate survival significant miRNAs, followed by miRNAs index accumulation to power the miRNAs-survival reliability. In the end, we test the selected miRNAs in HT126 colon cancer cells to validate its anti-cancer effect. The study identified a 84-miRNAs signature. Of the above 84 miRNAs, we got four miRNAs which were survival associated by using ROC curve method and Kaplan-Meier survival method (p < 0.001). The result showed that low risk group had quite a low death rate, the survival rate was over 80%. The high risk group had survival rate lower than 20%, which was also extremely lower than the overall survival rate. In the HT126 cells study, cell growth assay showed miR-130a sponge inhibited colon cancer cells growth and sensitized the anti-cancer drug effect of 5-FU to blocked cancer cell growth. We developed a prognostic 4-microRNA expression signature for colon cancer patient survival, and validated miR-130a sponge could sensitized 5-FU anti-cancer effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.